About RegenMed
RegenMed is a company based in Greenwich (United States) founded in 2014 by Michael Tierney and J William Futrell. RegenMed has raised $290 thousand across 1 funding round. RegenMed offers products and services including inCytes™, Benchmarc™, and Circles. RegenMed operates in a competitive market with competitors including Fauna Bio, Predxbio, BeaconCure, Humaneva Group and Private Health Management, among others.
- Headquarter Greenwich, United States
- Founders Michael Tierney, J William Futrell
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Regenmed, Inc.
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$290 K (USD)
in 1 rounds
-
Latest Funding Round
$290 K (USD), Seed
Feb 05, 2025
-
Investors
Not available
-
Employee Count
Not available
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of RegenMed
RegenMed offers a comprehensive portfolio of products and services, including inCytes™, Benchmarc™, and Circles.
Platform for healthcare data analysis and validation processes
System for medical research protocols and outcomes tracking
Network for physician-designed studies and data monetization
People of RegenMed
Unlock access to complete
Unlock access to complete
Funding Insights of RegenMed
RegenMed has successfully raised a total of $290K through 1 strategic funding round. The most recent funding activity was a Seed round of $290 thousand completed in February 2025. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investments & Acquisitions by RegenMed
Investment portfolio details for RegenMed
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - RegenMed
Detailed financials for RegenMed
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Regenmed Comparisons
Peer comparison for RegenMed
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of RegenMed
RegenMed operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Fauna Bio, Predxbio, BeaconCure, Humaneva Group and Private Health Management, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Animal genomics is applied to healthcare advancements by Fauna Bio.
|
|
| Locked | Locked | Locked |
AI-based drug discovery and clinical services are provided for biopharma.
|
|
| Locked | Locked | Locked |
Data analytics and validation software for regulatory submission in the healthcare sector
|
|
| Locked | Locked | Locked |
Provider of clinical research data services for oncology & other therapeutic areas
|
|
| Locked | Locked | Locked |
Provides personalized healthcare guidance for complex diseases and partnerships.
|
|
| Locked | Locked | Locked |
Develops AI-driven drugs for brain and CNS cancers through research and clinical trials.
|
Detailed competitors of RegenMed
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Regenmed
Complete news archive for RegenMed
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about RegenMed
RegenMed was founded in 2014 and raised its 1st funding round 11 years after it was founded.
RegenMed is headquartered in Greenwich, United States. It is registered at Greenwich, Connecticut, United States.
Michael Tierney is the current CEO of RegenMed. They have also founded this company.
RegenMed is a funded company, having raised a total of $290K across 1 funding round to date.
RegenMed was founded in 2014 in Greenwich, United States, as a healthcare technology firm specializing in translational regenerative medicine. A platform has been developed for collecting and analyzing real-world evidence to support medical research. Operations serve a global client base in the healthcare data sector, with services focused on clinical and financial outcomes for clinicians. Partnerships with leading healthcare organizations have been established, alongside backing from investors.
RegenMed's top competitors include Fauna Bio, Predxbio and BeaconCure.
RegenMed offers inCytes™, Benchmarc™, and Circles.